Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
Recognify Life Sciences, a subsidiary of atai Life Sciences (NASDAQ:ATAI), announced that its Phase 2b clinical trial for inidascamine in treating cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint of statistical significance. The study, involving 242 patients across the US and Europe, showed modest numerical improvements in cognitive and functional measures.
Despite not achieving statistical significance, inidascamine demonstrated consistent improvement across multiple cognitive domains and maintained a favorable safety profile with no sedation, weight gain, or extrapyramidal symptoms. The company will continue analyzing secondary endpoints and subgroup data to identify potential responder populations and guide future development.
Recognify Life Sciences, una controllata di atai Life Sciences (NASDAQ:ATAI), ha annunciato che il suo studio clinico di Fase 2b su inidascamine per il trattamento del deficit cognitivo associato alla schizofrenia (CIAS) non ha raggiunto l'endpoint primario di significatività statistica. Lo studio, che ha coinvolto 242 pazienti negli Stati Uniti e in Europa, ha mostrato miglioramenti numerici modesti nelle misure cognitive e funzionali.
Nonostante non abbia raggiunto la significatività statistica, inidascamine ha dimostrato un miglioramento costante in diversi domini cognitivi e ha mantenuto un profilo di sicurezza favorevole senza sedazione, aumento di peso o sintomi extrapiramidali. L'azienda continuerà ad analizzare gli endpoint secondari e i dati dei sottogruppi per identificare potenziali popolazioni rispondenti e orientare lo sviluppo futuro.
Recognify Life Sciences, una subsidiaria de atai Life Sciences (NASDAQ:ATAI), anunció que su ensayo clínico de Fase 2b para inidascamine en el tratamiento del deterioro cognitivo asociado a la esquizofrenia (CIAS) no alcanzó el objetivo primario de significancia estadística. El estudio, que involucró a 242 pacientes en EE. UU. y Europa, mostró mejoras numéricas modestas en las medidas cognitivas y funcionales.
A pesar de no lograr significancia estadística, inidascamine demostró una mejora constante en múltiples dominios cognitivos y mantuvo un perfil de seguridad favorable sin sedación, aumento de peso ni síntomas extrapiramidales. La compañía continuará analizando los objetivos secundarios y los datos de subgrupos para identificar posibles poblaciones respondedores y guiar el desarrollo futuro.
Recognify Life Sciences는 atai Life Sciences (NASDAQ:ATAI)의 자회사로서, 조현병 관련 인지장애(CIAS) 치료를 위한 inidascamine의 2b상 임상시험이 주요 통계적 유의성 목표를 달성하지 못했다고 발표했습니다. 미국과 유럽에서 242명의 환자를 대상으로 진행된 본 연구는 인지 및 기능 측정에서 미미한 수치상의 개선을 보였습니다.
통계적 유의성 달성에는 실패했지만, inidascamine은 여러 인지 영역에서 일관된 개선을 나타냈으며, 진정, 체중 증가, 추체외로 증상 없이 우수한 안전성 프로필을 유지했습니다. 회사는 2차 평가항목 및 하위 그룹 데이터를 추가 분석하여 잠재적 반응군을 식별하고 향후 개발 방향을 모색할 예정입니다.
Recognify Life Sciences, une filiale de atai Life Sciences (NASDAQ:ATAI), a annoncé que son essai clinique de phase 2b sur inidascamine pour le traitement des troubles cognitifs associés à la schizophrénie (CIAS) n'a pas atteint son critère principal de significativité statistique. L'étude, impliquant 242 patients aux États-Unis et en Europe, a montré des améliorations numériques modestes dans les mesures cognitives et fonctionnelles.
Bien que la significativité statistique n'ait pas été atteinte, inidascamine a démontré une amélioration constante dans plusieurs domaines cognitifs et a maintenu un profil de sécurité favorable sans sédation, prise de poids ou symptômes extrapyramidaux. La société poursuivra l'analyse des critères secondaires et des données des sous-groupes afin d'identifier d'éventuelles populations répondeuses et d'orienter les développements futurs.
Recognify Life Sciences, eine Tochtergesellschaft von atai Life Sciences (NASDAQ:ATAI), gab bekannt, dass die Phase-2b-Studie zu inidascamine zur Behandlung von kognitiven Beeinträchtigungen im Zusammenhang mit Schizophrenie (CIAS) den primären Endpunkt der statistischen Signifikanz nicht erreicht hat. Die Studie mit 242 Patienten in den USA und Europa zeigte moderate numerische Verbesserungen bei kognitiven und funktionalen Messungen.
Trotz des Ausbleibens der statistischen Signifikanz zeigte inidascamine konsistente Verbesserungen in mehreren kognitiven Bereichen und wies ein günstiges Sicherheitsprofil ohne Sedierung, Gewichtszunahme oder extrapyramidale Symptome auf. Das Unternehmen wird weiterhin sekundäre Endpunkte und Subgruppendaten analysieren, um potenzielle Responder-Populationen zu identifizieren und die zukünftige Entwicklung zu steuern.
- Favorable safety profile with no common side effects like sedation or weight gain
- Showed consistent numerical improvements across multiple cognitive measures
- Demonstrated positive effects on real-world functional cognitive capacity (VRFCAT)
- Potential applications in other cognitive impairment indications
- Failed to meet primary endpoint of statistical significance in Phase 2b trial
- Parent company atai Life Sciences plans to focus resources elsewhere
- Uncertain future development path for the drug
- Complex therapeutic area with significant development challenges
Insights
Recognify's Phase 2b trial for schizophrenia cognitive treatment failed its primary endpoint despite some positive signals and good safety profile.
Recognify Life Sciences has reported that its Phase 2b trial of inidascamine for cognitive impairment in schizophrenia failed to meet its primary endpoint of statistical significance on the MCCB neurocognitive composite score. While disappointing, the data reveals modest numerical improvements across several cognitive domains and functional measures compared to placebo, suggesting some biological activity.
The trial's design was robust - a randomized, double-blind, placebo-controlled study with 242 patients across the US and Europe testing two dose levels over six weeks. The safety profile remains favorable with no concerning signals like sedation, weight gain, or extrapyramidal symptoms that typically plague schizophrenia treatments.
Despite the missed primary endpoint, several factors warrant attention: (1) consistent directional improvements across multiple cognitive domains, particularly in Symbol Coding, Speed of Processing, and Verbal Learning; (2) positive signals on the VRFCAT functional capacity assessment; and (3) a clean safety profile in a population sensitive to side effects.
This outcome illustrates the significant challenge in developing CIAS treatments, where even modest cognitive improvements can be clinically meaningful but difficult to demonstrate statistically. The parent company atai's statement about resource allocation to their wholly-owned psychedelic candidates suggests reduced corporate support for this program moving forward, though Recognify appears to be exploring further analyses and potential development paths.
- Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo, but did not meet statistical significance on the primary endpoint
- Inidascamine continues to exhibit a favorable safety and tolerability profile
- Full data set, including secondary endpoints and subgroup analyses will be forthcoming
SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint.
While the study did not achieve statistical significance on its primary endpoint of improvement on the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB) neurocognitive composite score at Week 6, inidascamine demonstrated a modest but consistent numerical improvement across the overall MCCB neurocognitive composite and multiple individual subdomains, including Symbol Coding, Speed of Processing and Verbal Learning (immediate recall). Directionally positive effects were also observed on the Virtual Reality Functional Capacity Assessment Tool (VRFCAT), a measure of real-world functional cognitive capacity.
Inidascamine was well-tolerated, with a favorable safety profile consistent with previous studies. Importantly, no evidence of sedation, weight gain, or extrapyramidal symptoms was observed, which are side effects commonly associated with treatments used in people living with schizophrenia.
Matt Pando, PhD, Chief Executive Officer and Co-Founder of Recognify Life Sciences, commented: “Although we are disappointed that the study did not reach statistical significance on the primary efficacy endpoint, we are encouraged by the consistency of improvement signals across multiple cognitive and functional measures as well as replication on specific subsets of the cognitive measures; namely, symbol coding and verbal memory. These findings reinforce our commitment to addressing the significant unmet needs of cognitive impairment associated with numerous mental health and neurodegenerative conditions. Inidascamine continues to exhibit a strong safety profile, and we look forward to analyzing the full data set to better understand the outcome and inform potential next steps for the program.”
The randomized, placebo-controlled, double-blind, Phase 2b clinical study enrolled 242 patients across the United States and Europe (NCT05686239). The trial evaluated the efficacy, safety, and tolerability of two doses of inidascamine versus placebo over a six-week treatment period. A comprehensive analysis of remaining secondary and exploratory endpoints, including subgroup analyses, is ongoing to determine whether there are identifiable responder populations or mechanistic insights that may guide future development.
Keith Nuechterlein, PhD, Distinguished Professor in the UCLA Department of Psychiatry and Biobehavioral Sciences and co-chair of the MATRICS Neurocognition Committee, commented upon seeing these results: “Developing treatments for cognitive impairment in schizophrenia is a complex challenge that requires persistence and innovation. I am encouraged by the inidascamine topline results showing consistent directional tendencies for improvement and look forward to seeing the full set of results.”
Recognify plans to present additional results from the study at upcoming scientific meetings and will continue to evaluate strategic options for inidascamine based on the totality of data.
Srinivas Rao, MD, PhD, Chief Executive Officer and Co-Founder of atai Life Sciences, added: “CIAS remains a challenging therapeutic area with a significant unmet need. While we believe these results support the continued development of inidascamine by Recognify for CIAS as well as its potential application in other indications, as previously communicated, we intend to allocate atai’s resources on our wholly owned pipeline of transformative psychedelic product candidates focused on affective disorders."
About Inidascamine
Inidascamine, formerly RL-007, is an orally available compound, with unique mechanisms of action for the treatment of cognitive impairment, that modulates cholinergic, glutamatergic and GABA-B receptors, thereby putatively altering the excitatory/inhibitory balance in the brain to produce pro-cognitive effects. It has previously been evaluated in ten clinical studies, including one in the CIAS indication, with over 600 unique participants dosed to date. Clinical studies of inidascamine suggest improvement in cognitive performance, particularly for verbal learning and memory and processing speed.
About Schizophrenia and CIAS
Schizophrenia is a mental health disorder primarily characterized by hallucinations, delusions, and disordered thinking. This condition effects over 21 million people globally and approximately 2.4 million people in the United States, with around 300,000 new cases being diagnosed each year in the US. Cognitive deficits -present in approximately
About Recognify Life Sciences, Inc.
Recognify Life Sciences is a clinical-stage biotech company on a mission to provide pro-cognitive treatments solutions to mental health and neurodegenerative disorders. The company is a strategic investment of atai Life Sciences. For more information about Recognify, please visit www.recognify.life.
About atai Life Sciences
atai is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. atai’s pipeline of psychedelic-based therapies includes BPL-003 (mebufotenin benzoate) for treatment-resistant depression (TRD), which is being advanced through a planned strategic combination with Beckley Psytech Limited; VLS-01 (buccal film DMT) also for TRD; and EMP-01 (oral R-MDMA) for social anxiety disorder. All three programs are in Phase 2 clinical development. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD. These programs aim to address the complex nature of mental health providing commercially scalable interventional psychiatry therapies that can integrate seamlessly into healthcare systems. For the latest updates and to learn more about atai’s mission, visit www.atai.com or follow the Company on LinkedIn and on X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “initiate,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. All statements in this press release other than statements of historical fact are forward-looking statements, including, express or implied statements relating to, among other things: statements regarding Recognify Life Science’s inidascamine (formerly RL-007) studies, data, or related strategic plans and objectives of management for future operations, capital expenditures and capital allocation. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond our control and which could cause actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by these forward-looking statements.
Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in atai's other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.
Contact Information
Investor Contact:
IR@atai.com
atai Media Contact:
PR@atai.com
FAQ
What were the results of ATAI's Phase 2b trial for inidascamine in schizophrenia?
How many patients were enrolled in ATAI's inidascamine Phase 2b trial?
What safety profile did inidascamine demonstrate in ATAI's Phase 2b trial?
What is ATAI's next step for inidascamine development?
How will these trial results affect ATAI's business strategy?
